Stock Movers Novo Plunges, Santander Drops, LSEG Dips
Feb 4, 2026
Chloe Millay, Bloomberg markets reporter, breaks down major market movers. She explains Novo Nordisk's sales warning and the brewing obesity-drug price war. She covers Santander's $12bn Webster Financial deal and investor reaction. She also reviews LSEG's dip after AI-driven legal automation rattled software and financial stocks.
AI Snips
Chapters
Transcript
Episode notes
Price War Threatens Novo Nordisk Growth
- Novo Nordisk expects a steep drop in 2026 sales driven by intensifying pricing pressure in obesity drugs.
- Competition from Eli Lilly and cheaper copycats plus US drug-price caps are squeezing revenue and investor confidence.
Troubled Year and A Promising Pill Launch
- 2025 was a difficult year for Novo with leadership changes and trial setbacks that rattled investors.
- Despite those issues, the company launched an obesity pill that showed strong early uptake.
Santander Goes Big In The U.S.
- Santander is buying Webster Financial for $12 billion to expand in the US as part of a growth strategy.
- Investors worry shareholders preferred returns and that integration with Webster and TSB could be tricky.